Hamilton, NJ

Maheen Shah

Ash Research Clinic

Acute Coronary Syndrome

Heart Failure

JK07

Milvexian

Janssen (J&J Innovative Medicine)

Salubris Biotherapeutics

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.

There will be 2 cohorts in this study:

Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%.

Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.

Study of JK07 in Patients With Chronic Heart Failure

Ash Research Clinic | Brick, NJ

Site insights

Contact this site

Active trials

Study of JK07 in Patients With Chronic Heart Failure (RENEU-HF)

Trial sponsors